

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Kitsada Wudhikarn	POSITION TITLE Advanced Hematology Fellow in Lymphoma (Mayo) Assistant Professor of Medicine (Thailand)		
SPECIAL INTEREST Lymphoma, Adoptive Cellular Therapy, Immunotherapy, Comparative effectiveness research, database analysis			
OVERALL ACTIVITIES			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/DD/YY	FIELD OF STUDY/ACTIVITY
Chiang Mai University, Thailand	MD	05/27/97-03/03/03	Medicine
Chiang Mai University, Thailand	Resident	04//01/03-05/31/07	Internal Medicine
University of Minnesota, MN, USA	Resident	06/24/07-06/30/10	Internal Medicine
University of Iowa, IA, USA	Fellow	07/01/10-06/30/13	Hematology/Oncology
Stanford University, CA, USA	Fellow	07/01/13-06/30/14	Hematopoietic cell Transplant
Chulalongkorn University, Thailand	Instructor	09/01/14-06/21/18	Hematology
Chulalongkorn University, Thailand	Asst Prof	06/22/18-Present	Hematology
Memorial Sloan Kettering Cancer Center, NY, USA	Fellow	07/01/19-06/30/20	Cancer Immunotherapy
Mayo Clinic, MN, USA	Fellow	07/01/20-06/30/21	Advanced Hematology

1. Personal Statement

This biographical sketch has been composed to highlight my previous and ongoing experience and interest. My primary clinical and research focus have been in the area of lymphoproliferative disorders especially T cell lymphoma and various platforms of immunotherapy. I have been an active investigator involving in several clinical outcome researches and database analyses. I see myself to actively involved in precision medicine and integrating translational scientific aspect into my clinical research background in order to help me better understand the pathobiology of T cell lymphoma and its clinical implication on lymphoma management. My ultimate plan is to expand the knowledge I learn from the current project into the international collaborative project between my home institution in Thailand and other International organizations in the future.

2. Positions and Honors**Academic Positions and Employment**

04/2003-05/2007 Resident, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand
06/2007-06/2010 Resident, Department of Internal Medicine, University of Minnesota, Minneapolis, MN, USA
07/2010-06/2013 Fellow, Division of Hematology/Oncology/Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
07/2013-06/2014 Fellow, Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA, USA
09/2014-06/2018 Instructor, Division of Hematology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand
06/2018-Present Assistant Professor of Medicine, Division of Hematology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand (Position on hold during sabbatical leave 07/2019-06/2021)
07/2019-06/2020 Fellow, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York City, NY, USA (1st sabbatical year)
07/2020-06/2021 Fellow, Division of Hematology, Mayo Clinic, Rochester, MN, USA (2nd sabbatical year)

Other Experience and Professional Memberships

2003-	Active Member, Thai Medical Council
2007-	Active Member, The Royal College of Physician Thailand
2015-	Committee, Thai Lymphoma Study Group, Thai Society of Hematology
2015-	Active member, Thai Society of Hematology
2016-	Committee, Hematopoietic Stem Cell Transplant Group, Thai Society of Hematology
2016-	Active International member, American Society of Hematology

Awards & Honors

1998-2003	First in Class, Medical Student, Faculty of Medicine, Chiang Mai University
2003	Gold Medal Achievement award, First class honor, Doctor of Medicine (First Rank)
2003	Award for the most outstanding Thai medical graduate, The Somdetch Phra Mihitala Dhibesra Adulyadej Vikrom the Prince Father Foundation
2010	The best diagnostician award for graduated resident, Department of Medicine, University of Minnesota
2011	Novo Nordisk scholar for hematology fellow
2012	Clinical Research Training Institute Awardee, American Society of Hematology
2013	Merit Award, American Society of Clinical Oncology
2013	Travel Award, Iowa Oncology Society
2015	Global Oncology Fellow, American Society of Clinical Oncology
2019	ASH trainee abstract achievement award

3. Peer-reviewed Publications (in chronological order)

1. Garcia-Recio M., **Wudhikarn K.**, Pennisi M., Alonso-Trillo R., Flynn J., Shouval R., Afuye A.O., Silverberg M.L., Batlevi C.W., Parastoo D., Devlin S., Giralt S., Halton E., Ruiz J., Maloy M., Mead E., Palomba L., Santomasso B., Sauter C., Scordo C., Gunjan S., Perales M.A. The international prognostic index is associated with outcomes in diffuse large B cell lymphoma after CAR T cell therapy. *Biol Blood Marrow Transplant.* 2020 (Accepted)
2. **Wudhikarn K.**, Mailankody S., and Smith E.L. The Future of CAR T cells in Multiple Myeloma. *Hematology, the American Society of Hematology Education Program* 2020 (Accepted).
3. **Wudhikarn K.**, Loghavi S., Mangaonkar A.A., Al-Kali A., Binder M., Carr M., Reichard K., Finke C., Howard M., Gangat N., Tefferi A., Komrokji R., Ali N., Lasho T., Ketterling R., Padron E., and Patnaik M.M. SF3B1-mutant chronic myelomonocytic leukemia (CMML) defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. *Blood Adv.* 2020 (Accepted).
4. Polprasert C., Takeuchi Y., Makishima H., **Wudhikarn K.**, Kakiuchi N., Tangnuntachai N., Assanasen T., Sitthi W., Muhamad H., Lawasut P., Kongkiatkamon S., Bunworasate U., Izutsu K., Shiraishi Y., Chiba K., Tanaka H., Miyano S., Ogawa S., Yoshida K. and Rojnuckarin P. Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. *Leuk Lymphoma.* 2020 Sep 23:1-9.
5. Krittikarux K., **Wudhikarn K.**, Tangnuntachai N., Assanasen T., Sukswai N., Asawaphanumas T. and Chanswangphuwanana C. The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma. *Leuk Lymphoma.* 2020 Aug 21;1-9.
6. **Wudhikarn K.**, Palomba M.L., Pennisi M., Garcia-Recio M., Flynn J.R., Devlin S.M., Afuye A., Silverberg M.L., Maloy M.A., Batlevi C.L., Shah G.L., Scordo M., Dahi P.B., Sauter C.S., Santomasso B.D., Mead E., and Perales M.A. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. *Blood Cancer J.* 2020 Aug 5;10(8):79.
7. **Wudhikarn K.**, Pennisi M., Garcia-Recio M., Flynn J.R., Afuye A., Silverberg M.L., Maloy M.A., Devlin S.M., Batlevi C.L., Shah G.L., Scordo M., Palomba M.L., Dahi P.B., Sauter C.S., Santomasso B.D., Mead E., and Perales M.A. DLBCL Patients Treated With CD19 CAR T Cells Experience a High Burden of Organ Toxicities but Low Non-relapse Mortality. *Blood Adv.* 2020 Jul 14;4(13):3024-3033.
8. **Wudhikarn K.**, Bunworasate U., Julamanee J., Lekhakula A., Ekwattanakit S., Khuhapinant A., Niparuck P., Chuncharunee S., Numbenjapon T., Prayongratana K., Kanitsap N., Wongkhantee S., Makruasri N.,

- Wong P., Norasetthada L., Nawarawong W., Sirijerachai C., Chansung K., Suwanban T., Praditsuktavorn P., Intragumtornchai T. Event-free Survival at 12 Months Is a Strong Surrogate Endpoint for Stage 1 Diffuse Large B Cell Lymphoma: A Report From Nation Wide Registry Thai Lymphoma Study Group. *Leuk Lymphoma*. 2020 Jun 23;1-8. Online ahead of print.
9. **Wudhikarn K.** and Park J.H. Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: From basic to practice. *Leuk Lymphoma*. 2020 Jun 10;1-11. Online ahead of print.
 10. Pennisi M., Jain T., Santomasso B.D., Mead E., **Wudhikarn K.**, Silverberg M.L., Batlevi Y., Shouval R., Devlin S.M., Batlevi C., Brentjens R., Dahi P.B., Diamonte C., Giralto S., Halton E., Maloy M., Palomba M.L., Sanchez-Escamilla M., Sauter C., Scordo M., Shah G., Park J.H., Perales M.A. Comparing CAR T cells Toxicities Grading Systems: Application of ASTCT Grading System and Implications for Management. *Blood Adv*. 2020 Feb 25;4(4):676-686.
 11. **Wudhikarn K.**, Wills B., Lesokhin A. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action. *Best Pract Res Clin Haematol* 2020 Mar;33(1):101143.
 12. Aziz M.D., Shah J., Kapoor U., Dimopoulos C., Anand S., Augustine A., Ayuk F., Chaudhry M., Chen Y.B., Choe H.K., Etra A., Gergoudis S., Hartwell M.J., Hexner E.O., Hogan W.J., Kitko C.L., Kowalyk S., Kröger N., Merli P., Morales G., Nakamura R., Ordemann R., Pulsipher M.A., Qayed M., Reshef R., Rösler W., Schechter T., Schreiner E., Srinagesh H., Wöfl M., **Wudhikarn K.**, Yanik G., Young R., Özbek U., Ferrara J.L.M. and Levine J.E. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. *Leukemia*. 2020 Jul;34(7):1898-1906
 13. Srinagesh H.K., Özbek U., Kapoor U., Ayuk F., Aziz M., Ben-David K., Choe H.K., DeFilipp Z., Etra A., Grupp S.A., Hartwell M.J., Hexner E.O., Hogan W.J., Karol A.B., Kasikis S., Kitko C.L., Kowalyk S., Lin J., Major-Monfried H., Mielke S., Merli P., Morales G., Ordemann R., Pulsipher M.A., Qayed M., Reddy P., Reshef R., Rösler W., Sandhu K.S., Schechter T., Shah J., Sigel K., Weber D., Wöfl M., **Wudhikarn K.**, Young R., Levine J.E., Ferrara J.L.M. The MAGIC Algorithm Probability (MAP) is a validated response biomarker of treatment for acute graft-versus-host disease. *Blood Advances*. *Blood Adv*. 2019 Dec 10;3(23):4034-4042.
 14. Polprasert C., Takeda J., Niparuck P., Rattanathamthee T., Pirunsarn A., Suksusut A., Kobbuaklee S., **Wudhikarn K.**, Lawasut P., Kongkiatkamon S., Chuncharunee S., Songserm K., Phowthongkum P., Bunworasate U., Nannya Y., Yoshida K., Makishima H., Ogawa S., Rojnuckarin P. Novel DDX41 variants in Thai patients with myeloid neoplasms. *Int J Hematol*. 2019 Nov 11. [Epub ahead of print]
 15. **Wudhikarn K.**, Bunworasate U., Julamanee J., Lekhakula A., Ekwattanakit S., Khuhapinant A., Niparuck P., Chuncharunee S., Numbenjapon T., Prayongratana K., Kanitsap N., Wongkhantee S., Makruasri N., Wong P., Norasetthada L., Nawarawong W., Sirijerachai C., Chansung K., Suwanban T., Praditsuktavorn P., Intragumtornchai T. Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma. *Hematol Oncol*. 2019 Dec;37(5):578-585.
 16. Muhamad, H., Suksawai, N., Assanasen, T., Polprasert, C., Bunworasate, U. and **Wudhikarn, K.** Expression and clinical relevance of Programmed Cell Death-1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T cell Lymphoma. *Acta Haematol*. 2020;143(1):78-88.
 17. **Wudhikarn, K.**, Bunworasate, U., Julamanee, J., Lekhakula, A., Ekwattanakit, S., Khuhapinant, A., Chuncharunee, S., Niparuck, P., Khuhapinant, A., Numbenjapon, T., Prayongratana, K., Kanitsap, N., Wongkhantee, S., Makruasi, N., Wong, P., Norasetthada, L., Nawarawong, W., Sirijerachai, C., Chansung, K., Suwanban, T., Praditsuktavorn, P., and Intragumtornchai, T. Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group. *J Geriatr Oncol*. 2020 Jan;11(1):62-68.
 18. Limvorapitak W., Owattanapanich W., Utchariyaprasit E., Niparuck P., Puavilai T., Tantiworawit A., Rattanathamthee T., Saengboon S., Sriswasdi C., Julamanee J., Saelue P., Polprasert C., **Wudhikarn K.**, Wanitpongpun C., Prayongratana K. Better survivals in adolescent and Young adults, compared to adults with acute lymphoblastic leukemia - A multicenter prospective registry in Thai population. *Leuk Res*. 2019 Dec;87:106235.

19. Amnuay K., Srisawat N., **Wudhikarn K.**, Assanasen T., Polprasert C. Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients. *Hematol Rep.* 2019 Sep 18;11(3):8183.
20. Polprasert, C., Takeuchi, Y., Kakiuchi, N., Yoshida, K., Assanasen, T., Sitthi, W., Bunworasate, U., Pirunsarn, A., **Wudhikarn, K.**, Lawasut, P., Uaprasert, N., Kongkiatkamon, S., Moonla, C., Sanada, M., Akita, N., Takeda, J., Fujii, Y., Suzuki, H., Nannya, Y., Shiraiishi, Y., Chiba, K., Tanaka, H., Miyano, S., Rojnuckarin, P., Ogawa, S., Makishima, H. Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. *Blood Adv.* 2019 Feb 26;3(4):588-595.
21. Seresirikachorn, K., Norasetthada, L., Ausayakhun, S., Apivatthakakul, A., Tangchittam, S., Pruksakorn, V., **Wudhikarn, K.**, Wiwatwongwana, D. Clinical presentation and treatment outcomes of primary ocular adnexal MALT lymphoma in Thailand. *Blood Res.* 2018 Dec;53(4):307-313.
22. Major-Monfried, H., Renteria, A.S., Pawarode, A., Reddy, P., Ayuk, F., Holler, E., Efebera, Y.A., Hogan, W.J., Wöfl, M., Qayed, M., Hexner, E.O., **Wudhikarn, K.**, Ordemann, R., Young, R., Shah, J., Hartwell, M.J., Chaudhry, M., Aziz, M., Etra, A., Yanik, G.A., Kröger, N., Weber, D., Chen, Y.B., Nakamura, R., Rösler, W., Kitko, C.L., Harris, A.C., Pulsipher, M., Reshef, R., Kowalyk, S., Morales, G., Torres, I., Özbek, U., Ferrara, J.L.M., Levine, J.E. MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD. *Blood.* 2018 Jun 21;131(25):2846-2855.
23. Intragumtornchai, T., Bunworasate, U., **Wudhikarn K.**, Lekhakula, A., Julamane, J., Chansung, K., Sirijerachai, C., Norasetthada, L., Nawarawong, W., Khuhapinant, A., Siritanaratanakul, N., Numbenjapon, T., Prayongratana, K., Chuncharunee, S., Niparuck, P., Suwanban, T., Kanitsap, N., Wongkhantee, S., Pornvipavee, R., Wong, P., Makruasi, N., Wannakrairot, P., Assanasen, T., Sukpanichnant, S., Boonsakan, P., Kanoksil, W., Ya-In, C., Kayasut, K., Mitranun, W., Warnnissorn, N. Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. *Hematol Oncol.* 2018 Feb;36(1):28-36.
24. Hartwell, M.J., Özbek, U., Holler, E., Renteria, A.S., Major-Monfried, H., Reddy, P., Aziz, M., Hogan, W.J., Ayuk, F., Efebera, Y.A., Hexner, E.O., Bunworasate, U., Qayed, M., Ordemann, R., Wöfl, M., Mielke, S., Pawarode, A., Chen, Y.B., Devine, S., Harris, A.C., Jagasia, M., Kitko, C.L., Litzow, M.R., Kröger, N., Locatelli, F., Morales, G., Nakamura, R., Reshef, R., Rösler, W., Weber, D., **Wudhikarn, K.**, Yanik, G.A., Levine, J.E., Ferrara, J.L. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. *JCI Insight.* 2018 Aug 23;3(16). pii: 124015.
25. **Wudhikarn, K.**, Bunworasate, U., Julamane, J., Lekhakula, A., Chuncharunee, S., Niparuck, P., Ekwattanakit, S., Khuhapinant, A., Norasetthada, L., Nawarawong, W., Makruasi, N., Kanitsap, N., Sirijerachai, C., Chansung, K., Wong, P., Numbenjapon, T., Prayongratana, K., Suwanban, T., Wongkhantee, S., Praditsuktavorn, P., Intragumtornchai, T.; Thai Lymphoma Study Group. Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry. *Ann Hematol.* 2017 Jan;96(1):57-64.
26. **Wudhikarn, K.**, Smith, B.J., Button, A.M., Habermann, T.M., Thompson, C.A., Rosenstein, L.J., Syrbu, S.I., Weiner, G.J., Cerhan, J.R., Link, B.K. Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. *Leuk Lymphoma.* 2015;56(8):2365-72.
27. **Wudhikarn, K.** and Link B.K., Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges. *J Comp Eff Res.* 2014 Jan;3(1):95-107
28. **Wudhikarn, K.**, Colling, C., Robinson, R.A., and Vaena, D., Solitary bony metastasis in seminoma. *J Clin Oncol.* 2013 Jun 1;31(16):E259-61.
29. **Wudhikarn, K.**, Gingrich, R., and Silverman, M. Daptomycin Nonsusceptible enterococci in hematologic malignancy and hematopoietic stem cell transplant patients: An emerging threat. *Ann Hematol.* 2013 Jan;92(1):129-31.
30. **Wudhikarn, K.**, Van Rheeden, R., Leopold, C., Rattanaumpawan, P., Gingrich, R., and Silverman, M. Outcome of allogeneic stem cell transplantation in myelodysplastic syndromes patients: prognostic implication of monosomal karyotype. *Eur J Haematol.* 2012 Oct; 89(4):294-301
31. **Wudhikarn, K.** and Silverman M. Fatal Disseminated Intravascular Coagulation in acute promyelocytic leukemia. *Am J Hematol.* 2012 Mar;87(3):306-7.

32. **Wudhikarn, K.**, Perry E.H., Kemperman M., Jensen K.A., and Kline S.E. Severe Transfusion-Transmitted babesiosis in an immunocompromised patient: A case report and review of literature. *Am J Med.* 2011 Sep; 124(9):800-5.
33. **Wudhikarn, K.**, Brunstein, C.G., Bachanova, V., Burns, L.J., Cao, Q. and Weisdorf, D.J. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: Management strategies and outcome. *Biol Blood Marrow Transplant.* 2011 Oct; 17(10):1497-504
34. **Wudhikarn, K.**, Holman, C., Linan, M., Blaes, A.H., Dunitz, J.M., Hertz, M.E. and Peterson, B.A. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-year experience at the University of Minnesota. *Clin Transplant.* 2011 Sept; 25(5):705-13.
35. Dunning, K.K., **Wudhikarn, K.**, Safo, A.O., Holman, C.J., Mckenna, R.W. and Pambuccian, S.E. Adrenal Extranodal NK/T-cell lymphoma diagnosed by fine-needle aspiration and cerebrospinal fluid cytology and immunophenotypin: A case report. *Diagn Cytopathol.* 2009 Sep; 37(9):686-95.
36. Navaravong, L., **Wudhikarn, K.** and Marini, J.J. Idiopathic acute eosinophilic pneumonia; another reason for not smoking. *Cases J.* 2008 Dec; 1(1):414.

4. Abstracts and Posters Presentation (in chronological order)

1. **Wudhikarn K.**, Pennisi M., Recio M.G., Maloy M.A., Shah G., Scordo M., Dahi P., Sauter C., Batlevi C., Palomba M.L., Seo S., Perales M.A. Infectious complications in aggressive B cell non-Hodgkin lymphoma after CD-19 chimeric antigen receptor T cell therapy. (General poster presentation at the annual meeting American Society of Transplant and Cellular Therapy 2020, Orlando, Florida, USA).
2. **Wudhikarn K.**, Pennisi M., Recio M.G., Flynn J., Maloy M.A., Devlin S.M., Batlevi C., Shah G., Scordo M., Palomba M.L., Dahi P., Sauter C., Perales M.A. Burden and impact of toxicities on outcomes for aggressive B cell non-Hodgkin lymphoma patients after CD19-directed chimeric antigen receptor T cell: Real-world experience. (General poster presentation at the annual meeting American Society of Transplant and Cellular Therapy 2020, Orlando, Florida, USA).
3. **Wudhikarn K.**, Bunworasate U., Julamanee J., Lekhakula A., Ekwattanakit S., Khuhapinant A., Niparuck P., Chuncharunee S., Numbenjapon T., Prayongratana K., Kanitsap N., Wongkhantee S., Makruasri N., Wong P., Norasetthada L., Nawarawong W., Sirijerachai C., Chansung K., Suwanban T., Praditsuktavorn P., Intragumtornchai T. EFS12 Is a Powerful Predictive Tool for Outcomes in Stage I Aggressive Non Hodgkin Lymphoma: A Report from Nationwide Registry in a Resource Limited Country Thai Lymphoma Study Group. (General poster presentation at the annual meeting American Society of Hematology 2019, Orlando, Florida, USA).
4. **Wudhikarn, K.**, Bunworasate, U., Julamanee, J., Lekhakula, A., Ekwattanakit, S., Khuhapinant, A., Chuncharunee, S., Niparuck, P., Khuhapinant, A., Numbenjapon, T., Laoruangroj, C., Kanitsap, N., Wongkhantee, S., Makruasi, N., Wong, P., Norasetthada, L., Nawarawong, W., Sirijerachai, C., Chansung, K., Suwanban, T., Praditsuktavorn, P., and Intragumtornchai, T. Event Free Survival at 12 months and 24 months as predictors for outcome of nodal peripheral T cell lymphoma: Analysis of Nationwide Thai Lymphoma Study Group (General poster presentation at International Conference in Malignant Lymphoma 2019, Lugano, Switzerland).
5. Qayed M., Kapoor U., Gillespie S., Merli P., Pulsipher MA., Woelfl M., Kitko C., Abusin G., **Wudhikarn K.**, Schechter T., Young R., Ferrara J., and Levine JE. Disease Risk Index Predicts Relapse in Children Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT). (General poster presentation at the American Society for Transplant and Cellular Therapy 2019, Houston, Texas, USA).
6. Etra A., Gergoudis S., Morales G., Kowalyk S., Lin J., Shah J., Kapoor U., Aziz M., Pawarode A., Ayik F., Holler E., Choe H., Chen YB., Rosler W., Qayed M., Hogan WJ., Woelfl M., Hexner EO., Merli P., Kitko C., Malki MM., Reshef R., **Wudhikarn K.**, Ordemann R., Pulshipher MA., Mielke S., Schechter T., Ozbek U., Ferrara JLM., and Levine JE. Comparison of GVHD Biomarker Algorithms for Predicting Lethal Gvhd and Non-Relapse Mortality. (General poster presentation at the American Society for Transplant and Cellular Therapy 2019, Houston, Texas, USA).
7. **Wudhikarn, K.**, Bunworasate, U., Julamanee, J., Lekhakula, A., Ekwattanakit, S., Khuhapinant, A., Chuncharunee, S., Niparuck, P., Khuhapinant, A., Numbenjapon, T., Laoruangroj, C., Kanitsap, N., Wongkhantee, S., Makruasi, N., Wong, P., Norasetthada, L., Nawarawong, W., Sirijerachai, C.,

- Chansung, K., Suwanban, T., Praditsuktavorn, P., and Intragumtornchai, T. Characteristics, treatment patterns, prognostic determinants and outcome of elderly peripheral T cell non-Hodgkin Lymphoma in a resource-limited country: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group. (Oral presentation at the 80th Annual Meeting of the Japanese Society of Hematology 2018, Osaka, Japan).
8. Muhamad H., Suksawai N., Assanasen T., Polprasert C., Bunworasate U., and **Wudhikarn K.** Expression and clinical relevance of Programmed Cell Death-1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T cell Lymphoma. (Oral presentation at the 80th Annual Meeting of the Japanese Society of Hematology 2018, Osaka, Japan) (**Wudhikarn K is the corresponding author**)
 9. Polprasert C., Takeuchi Y., Makishima H., **Wudhikarn K.**, Kakiuchi N., Yoshida K., Assanasen T., Sitthi W., Bunworasate U., Lawasut P., Kongkiatkamon S., Rojnuckarin P., and Ogawa S. Novel genetic events of human leukocyte antigen in NK/T cell lymphomas. (Oral presentation at the 80th Annual Meeting of the Japanese Society of Hematology 2018, Osaka, Japan)
 10. **Wudhikarn, K.**, Bunworasate, U., Julamane, J., Lekhakula, A., Ekwattanakit, S., Khuhapinant, A., Chuncharunee, S., Niparuck, P., Khuhapinant, A., Numbenjapon, T., Prayongratana, K., Kanitsap, N., Wongkhantee, S., Makruasi, N., Wong, P., Norasetthada, L., Nawarawong, W., Sirijerachai, C., Chansung, K., Suwanban, T., Praditsuktavorn, P., and Intragumtornchai, T. Characteristics, treatment patterns, prognostic determinants and outcome of elderly peripheral T cell non-Hodgkin Lymphoma in a resource-limited country: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group. (General poster presentation at European Hematology Association 2018, Stockholm, Sweden)
 11. **Wudhikarn, K.**, Bunworasate, U., Lekhakula, A., Julamane, J., Sirijerachai, C., Chansung, K., Norasetthada, L., Nawarawong, W., Khuhapinant, A., Ekwattanakit, S., Numbenjapon, T., Prayongratana, K., Chuncharunee, S., Niparuck, P., Suwanban, T., Kanitsap, N., Wongkhantee, S., Pornvipavee, R., Wong, P., Makruasi, N., Praditsuktavorn, P., and Intragumtornchai, T. Validation of German High-Grade Non-Hodgkin's Lymphoma (DSHNHL) Prognostic Model and the Impact of Treatment on Secondary Central Nervous System (CNS) Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) in a Developing Country: Report from the Nationwide Multi-Institutional Registry of Thai Lymphoma Study Group (TLSG) (General poster presentation at American Society of Hematology 2015, Orlando, Florida, USA).
 12. Lawasut, P., Chanswangphuwana, C., **Wudhikarn, K.**, Kijrattanakul, P., Chaiyapan, U., Polprasert, C., Uaprasert, N., Rojnuckarin, P., Intragumtornchai, T., Bunworasate, U. and Na-Nakorn, T. Effect of high dose melphalan administration schedule: Comparison between 1-Day and 2-Day dose for myeloma conditioning regimen. (General poster presentation at the 15th international myeloma workshop 2015, Rome, Italy).
 13. **Wudhikarn, K.**, Lavori, P., Arai, S., Johnston, L., Laport, G.G., Lowsky, R., Miklos, D.B., Shizuru, J.A., Hoppe, R.T., Benjamin, J., Meyer, E., Negrin, R., and Weng, W. Outcome of tandem autologous/allogeneic hematopoietic cell transplantation in high-risk non-Hodgkin's lymphoma patients: Stanford University Experience (General poster presentation at ASBMT Annual tandem meeting 2014, Grapevine, Texas).
 14. **Wudhikarn, K.**, Button, A.M., Smith, B.J., Habermann, T.M., Thompson, C.A, Cerhan, J.R., Link, B.K. Correlation of chemotherapy delivery and survival outcomes of follicular lymphoma in the immunochemotherapy era. (General poster presentation American Society of Clinical Oncology 2013, Chicago, Illinois, USA).
 15. **Wudhikarn, K.**, Van-Rheeden, R., Leopold, C., Rattana-umpawan, P. and Silverman, M. Outcome of allogeneic stem cell transplant in MDS patients with monosomal karyotype (Poster presentation at American Society of Bone Marrow Transplant Tandem Meeting 2012, San Diego, California, USA).
 16. **Wudhikarn, K.**, Gingrich, K. and Margarida, S. Venous thromboembolism in allogeneic stem cell transplantation – The incidence, characteristics and management – A single institution experience (General poster presentation at American Society of Bone Marrow Transplant Tandem Meeting 2012, San Diego, California, USA).

17. **Wudhikarn, K.**, Brunstein, C.G., Bachanova, V., Burns, L.J., Cao, Q. and Weisdorf, D.J. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: Management strategies and outcome. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 4503.
18. **Wudhikarn, K.**, Perry E.H., Kemperman M., Jensen K.A., and Kline S.E. Severe Transfusion-Transmitted babesiosis in an immunocompromised patient. Poster presentation at ACP Annual Meeting MN Chapter 2009, Rochester, Minnesota, USA.
19. **Wudhikarn, K.**, Holman, C., Linan, M., Blaes, A.H., Dunitz, J.M., Hertz, M.E. and Peterson, B.A. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-year experience at the University of Minnesota. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 3947, New Orleans, Louisiana, USA. (General poster presentation at American Society of Hematology Annual Meeting 2009, New Orleans, Louisiana, USA).
20. **Wudhikarn, K.**, Skubitz, K.J. and Gupta, A.P. Hemobilia: An uncommon complication of portal vein embolization. Poster presentation at ACP Annual Meeting MN Chapter 2008, Minneapolis, Minnesota, USA.
21. **Wudhikarn, K.**, Wangkaew, S. and Louthrenoo, W. Use of COX-2 specific NSAIDs at Maharaj Nakorn Chiang Mai Hospital. Oral presentation at Thai Medical Association Annual Meeting 2007, Chonburi, Thailand.

5. Research Support

Ongoing Research Support

SPORE Internal Grant (Bennani)

07/1/2020-06/30/2021

Mayo/University of Iowa internal SPORE Grant

70,000 USD

Dr. Bennani serves as the principle investigator on the project "Comprehensive Multi-Omics Analysis of Angioimmunoblastic T cell Lymphoma"

Thai Society of Hematology Research Grant for Young Investigator

06/1/2019-Present

Kitsada Wudhikarn (Principal Investigator)

200,000 Baht

Cell of origin of patients with diffuse large B cell lymphoma in Thailand